FDA granted approval today to Camber Pharmaceuticals for Mycophenolate Mofetil oral tablets, expanding its 2 mg strength to a 500 mg dosage in response to market demand. The finalization of this ANDA will provide a cost-effective alternative for prescribers and potentially drive competition within the immunosuppressive therapy sector.